Events
Alzheimer's Disease International Conference, July 26-29, 2018
Oral presentation as part of "Women and Dementia” parallel session: "Female caregivers’ perspectives on the most important outcomes of Alzheimer’s disease and dementia". C. Tochel, Alzheimer's Disease International Conference 2018, 27 July (4 pm), Chicago (USA). Find more information about the conference here.

Roadmap Female caregivers’ perspectives on the most important outcomes of Alzheimer’s disease and dementia International
32nd ESPMH Conference, August 22-25, 2018
Oral presentation: “Neuroethics in dementia prevention”. A. McKeown, 32nd European Conference on philosophy of medicine and health care, 24 August, Lisbon (Portugal). Find the programme here.
14th G-I-N 2018, September 12-14, 2018
Why we do what we do: the purpose and impact of guidelines
Poster presentation: "The value of an Expert Advisory Group: Exploration of barriers and facilitators within the ROADMAP international big data project". D. O'Rourke, et al., Guidelines International Network, 12-14 September 2018, Manchester (UK). Find the programme here.

6th GA Meeting ROADMAP project, October 8-9, 2018
The 6th ROADMAP General Assembly Meeting is planned to take place during October in Barcelona (Spain).



  Are you interested to learn more about ROADMAP and its activities? Contact us at info@roadmap-alzheimer.org
IMI 10th anniversary scientific symposium, October 22-23 , 2018
  • Poster presentation: "Identifying priority outcomes and understanding meaningful delay in disease progression for Alzheimer’s Disease across the spectrum". A. Ly, IMI 10th anniversary scientific symposium, 22-23 October, Brussels (Belgium).
  • Poster presentation: "Alignment of European regulatory and health technology assessments: a review of licensed products for Alzheimer’s disease". M. Dekker, IMI 10th anniversary scientific symposium, 22-23 October, Brussels (Belgium).


Find out more about the symposium here.  
28th Alzheimer Europe Conference, October 29-31, 2018
Presentation: "Important outcomes of Alzheimer’s disease from the perspective of people with the disease & their supporters". C. Tochel et al., 28th Alzheimer Europe Conference, 29-31 October, Barcelona, (Spain).

Presentation: "Challenges of including patient-relevant outcomes in funding decisions for Alzheimer’s disease drugs, and consequences – A health technology assessment perspective". A. Bauer & R. Wittenberg, 28th Alzheimer Europe Conference, 29-31 October, Barcelona, (Spain).

Find the programme here.

 
Past presentations
  • Panel session: “The state of Alzheimer’s disease in Europe - innovation, value and challenges for HTA”. J. Bouvy, J. Georges, R. Handels, M. Knapp & C. Reed, Health Technology Assessment international (HTAi) Annual Meeting,17-21 June 2017, Rome (Italy).
  • Poster presentation: "Overcoming ethical issues in sharing real-world evidence in Alzheimer’s disease: The ROADMAP Project”. J. Krutzinna, Neuroethics Network 2017, 19-21 June 2017, Paris (France).
  • Poster presentation: “Real World Evidence for Alzheimer’s disease Outcomes”, Alzheimer's Association International Conference (AAIC), 16-20 July 2017, London (UK).
  • Oral presentation: “Actualités sur l’Aducanumab et étude ROADMAP”. Journées scientifiques de la fédération nationale des Centres Mémoire Ressources Recherche (FCMRR), 28-29 September 2017, Montpellier (France).
  • Symposium: “Engaging with patient organizations within IMI consortia to inform quality, relevance and value in Alzheimer’s research – insights from MOPEAD, EPAD and ROADMAP”. As part of Lilly symposium, Alzheimer Europe Conference, 2-4 October 2017, Berlin (Germany).
  • Poster presentation: “Challenges in Optimising Real World Evidence for Alzheimer’s Disease”. C. Reed, F. de Reydet de Vulpillieres, J. Gallacher, Clinical Trials on Alzheimer’s Disease (CTAD 2017), 1-4 November 2017, Boston, MA (USA).
  • Oral presentation: “Challenges in Optimizing Real World Evidence for Alzheimer’s Disease”. C. Reed, F. de Reydet de Vulpillieres, J. Gallacher, International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Annual European Congress, 4-8 November 2017, Glasgow (UK). http://www.sciencedirect.com/science/article/pii/S1098301517303716
  • Poster presentation: "A model for Alzheimer’s disease in the prevention setting". N. Hummel, et al., International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Annual European Congress 2017, 4-8 November 2017, Glasgow (UK).
  • Oral presentation: "The aims of the ROADMAP project". C. Reed, Alzheimer Association Academy, 5-6 December 2017, Brussels (Belgium).
  • Oral presentation: "The use of real-world data and evidence in regulatory and health technology assessments". M. Dekker, Alzheimer Association Academy, 5-6 December 2017, Brussels (Belgium).
  • Oral presentation: "Ethical issues raised by big data and real-world evidence projects". A. Turner, Alzheimer Association Academy, 5-6 December 2017, Brussels (Belgium).
  • Oral presentation: "Expert advisory involvement in ROADMAP". A. Santuccione Chadha, Closed meeting at Lausanne IV, 13 December 2017, Lausanne (Switzerland).
  • Poster presentation: “Real World Outcomes across the Alzheimer’s Disease spectrum for better care: Multi-modal data Access Platform”. O. Janssen, S. Vos, R. Handels, F. Verhey, P. J. Vissser,  Symposium: The Future of a Data-Driven Society, 25 January 2018, Maastricht (the Netherlands).
  • Oral presentation: “Real-world evidence in Alzheimer’s disease: the ROADMAP collaboration”. P. J. Visser, International Pharmaco-Economic Conference on Alzheimer's Disease (IPECAD), 15-16 February 2018, Paris (France).
  • Oral presentation: "Data sharing in biomedical research: practical questions". C. Diaz, XI Annual Conference of Technological Platforms in Biomedical Research, 5 March 2018, Barcelona (Spain).
  • Oral presentation: "Real world evidence for investigating AD outcomes: utilising platform resources". N. Vaci, IMI-EMIF Symposium ‘Liberating Evidence from European Health Data – the Achievements and Challenges of a Five-Year IMI Project’, 18 April 2018, Brussels (Belgium).
  • Poster presentation: "Predictive modelling for secondary prevention of Alzheimer's disease: Ethical concerns and social implications based on targeted, narrative literature review". Z. Angehrn, et al., International Society For Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting, 19-23 May 2018, Baltimore MD (USA).
  • Oral presentation: “Regulatory and HTA considerations in Alzheimer’s disease”. J. Bouvy, HTAi 2018 Meeting, 5 June 2018, Vancouver (Canada).
  • Roundtable discussion: “Real world data and dementia: contributions from the Information System for the development of primary care research (SIDIAP) and the Girona Dementia Register (ReDeGi)”. A. Ponjoan, 11th Research Day of the IDIAPJGol and the 10th Research Day of Catalan Health Institute (ICS), 7 June, Barcelona (Spain).
  • Oral presentation: “Neuroethics in Dementia Prevention and Treatment: Early intervention for better life long brain health. Findings from the ROADMAP project”. A. McKeown, 5th Institute of Medical Ethics Summer Conference, 19-20 June, Oxford (UK).
  • Oral presentation: "Health-related quality of life in people with dementia measured with preference based instruments: a systematic literature review and meta-analysis". F. Landeiro, et al., XXXVIII Jornadas de Economía de Salud, 21 June 2018, Las Palmas (Spain).
  • Two of our ROADMAP teams (Outcome Definition and ELSI) met with the members of the Eueopean Working Group of People With Dementia for an interactive feedback session, presenting, discussing and refining conclusions from their consultations in two seperate sessions, on 27 June 2018, Brussels (Belgium).